February 15, 2012 — The US Food and Drug Administration (FDA) has approved a urine-based molecular assay (Progensa, Gen-Probe) that helps determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
The test, which is already approved and marketed in Europe and Canada, detects levels of prostate cancer gene 3 (PCA3), which is overexpressed in "virtually all prostate carcinoma specimens," according to an independent review published last year (Nat Rev Urol. 2011;8:123-124).
The PCA3 assay is indicated for helping to decide whether men 50 years or older who have had 1 or more previous negative prostate biopsy, and "for whom a repeat biopsy would be recommended by a urologist based on the current standard of care," should undergo a repeat biopsy, according to the company.
Such men have been described as having a "PSA dilemma" — that is, an elevated PSA score but negative biopsies.
FDA approval of the PCA3 assay was based on a clinical study that enrolled 495 eligible men at 14 clinical sites. In the study, the PCA3 assay had a negative predictive value of 90%, meaning that a negative result predicted a negative prostate biopsy 90% of the time, according to the company.
The pivotal clinical study of the assay only looked at men who were recommended for repeat biopsy. The assay's performance has not been established in men for whom a repeat biopsy is not already recommended.
"PCA3 provides direct detection of prostate cancer cells," explained Jack Groskopf, PhD, director of research and development in cancer diagnostics at Gen-Probe, at the 2010 Genitourinary Cancer Symposium.
Unlike PSA, it is not expressed in other prostate disorders, such as prostatitis or benign prostatic hyperplasia, he said at a press conference that covered a study of the assay presented at the meeting.
2 σχόλια:
Hey! I am glad to stop by your site and know more about cancer assays. Keep it up! This is a good read. You have such an interesting and informative page. I will be looking forward to visit your page again and for your other posts as well. Thank you for sharing your thoughts about cancer assays in your area.
Following gene identification and algorithm development, a process for conducting the assay, including all steps from receipt of the tumor specimen to generation of the assay result, was finalized and analytically validated prior to conducting clinical validation studies. Analytical validation of Oncotype DX test ensures that the assay will give accurate, precise and reproducible results across different reagent lots, operators, and patient samples. Standardization of the assay is critical to ensuring that the Oncotype DX assay yields reliable results which clinicians can use to informing patient management treatment decisions.
Off-the-shelf Mass Spectrometry assay service available through ISO 9001:2008 accredited facility.
Cancer Assays
Pretty good post. I just stumbled upon your blog and wanted to say that I have really
enjoyed reading your blog posts.
custom assay development
Δημοσίευση σχολίου